Media about us

08 July 2016

EyewireTV – FDA Approves Raindrop Inlay; Humira for Uveitis Treatment

EyeWire Today

In this week’s EyewireTV, ReVision Optics receives FDA approval for the Raindrop Near Vision Inlay, the first implantable device that changes the shape of the cornea to achieve improved vision; and the FDA approves Humira (adalimumab) for the treatment of noninfectious intermediate and posterior uveitis and panuveitis. Also, Bausch + Lomb and Nicox announce that the results of a phase 3 study of glaucoma drug candidate latanoprostene bunod have been published in the American Journal of Ophthalmology.

07 July 2016

Test Aids Prostate Cancer Treatment

Ron Winslow / The Wall Street Journal

Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival. The test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.

30 June 2016

New blood test from Epic Sciences matches patients with PARP inhibitors

Josh Baxt / MedCityNews

San Diego-based liquid biopsy company Epic Sciences has announced a new blood test that may quickly identify cancer patients who respond to a promising class of drugs called poly ADP ribose polymerase (PARP) inhibitors. The test works by identifying circulating tumor cells (CTCs) affected by homologous recombination deficiency (HRD), a damaged DNA repair mechanism.

28 June 2016

Epic Sciences unveils new, more sensitive biopsy test to detect a range of cancers

Joseph Keenan / Fierce Medical Devices

San Diego's Epic Sciences has added a new liquid biopsy test to its arsenal of biopharma cancer detection tools that targets homologous recombination deficiencies (HRDs) in individual circulating tumor cells.

20 June 2016

BIO-Europe Spring® 2016: RMI says it has USD 200 million already under management

EBD Group

Maxim Gorbachev, a partner and portfolio manager at RusnanoMedInvest (RMI) speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio about Russia’s and Eastern Europe’s largest venture capital company, specializing in innovative developments in the field of pharmaceuticals and biotechnology. 

09 June 2016

Treatment for age related loss of near vision: Raindrop near vision inlay one-year clinical results

Jeffrey Whitman, MD Key-Whitman Eye Center, Dallas, TX, USA / Atlas of Science

Presbyopia is an ocular condition associated with age related loss of near vision. The eye loses the ability to focus well on near objects due to the hardening of the natural lens. It affects billions of people worldwide with the onset occurring around age 45. The most common treatment for presbyopia is the use of reading glasses. Recently, surgical correction of presbyopia has been tested as part of a clinical study by implanting a small device into the cornea, the clear front part of the eye.  The Raindrop Near Vision Inlay is an investigational device that is being evaluated to treat this condition so that dependence upon reading glasses may be reduced in order to see objects up close.

13 May 2016

Good long-term visual acuities reported in presbyopic patients implanted with Raindrop inlay

Healio

Good long-term visual acuities for distance and near were achieved in presbyopic patients, both emmetropic and hyperopic, implanted with the ReVision Optics Raindrop inlay, according to a study presented by Cornelis Verdoorn, MD, at the American Society of Cataract and Refractive Surgery meeting here.

Clearside Biomedical Announces Potential Pricing for IPO

Chris Lange / 24/7 Wall St.

Clearside Biomedical has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its 4 million shares in the range of $14 to $16 per share, with an overallotment option for an additional 600,000 shares. At the maximum price the entire offering is valued up to $73.6 million. The company intends to list its shares on the Nasdaq Global Market under the symbol CLSD.

18 April 2016

Marinus Pharmaceuticals Receives Orphan Drug Status for Ganaxolone as Treatment for Status Epilepticus

Robin Reyes / SonoranWeeklyReview.com

Marinus Pharmaceuticals (NASDAQ:MRNS) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ganaxolone for the treatment of status epilepticus, according to the agency’s website. Status epilepticus is a dangerous condition in which epileptic seizures follow one another without recovery of consciousness between them. 

05 April 2016

Breaking the Test Tube Ceiling

Josh Baxt / San Diego Magazine

At a recent high school night, curious middle schoolers and parents listened intently as schools talked up their programs. The speeches were formulaic, and mercifully brief, but at one point, the rep from a technology-oriented high school targeted a specific audience. “Girls,” she said, “don’t let the tech part scare you.”